These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29631441)

  • 1. Intraocular light scatter in patients on topical intraocular pressure-lowering medication.
    Pérez-Bartolomé F; Martínez de la Casa JM; Arriola-Villalobos P; Fernández-Pérez C; García-Feijoó J
    Eur J Ophthalmol; 2018 Nov; 28(6):652-661. PubMed ID: 29631441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
    Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
    Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular Redness Measured with the Keratograph 5M in Patients Using Anti-Glaucoma Eye Drops.
    Pérez Bartolomé F; Martínez de la Casa JM; Arriola Villalobos P; Fernández Pérez C; Polo V; Sánchez Jean R; García Feijoó J
    Semin Ophthalmol; 2018; 33(5):643-650. PubMed ID: 29144869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tear film osmolarity in patients treated for glaucoma or ocular hypertension.
    Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C
    Cornea; 2012 Sep; 31(9):994-9. PubMed ID: 22710490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of objective ocular redness measured with Keratograph 5M in glaucoma patients after instilling brimonidine drops.
    Montolío-Marzo E; Fernández-Narros R; Morales-Fernández L; García-Bella J; Sáenz-Francés F; García-Feijoo J; Martínez-de-la-Casa JM
    Eur J Ophthalmol; 2024 Mar; 34(2):480-486. PubMed ID: 37661653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.
    Saade CE; Lari HB; Berezina TL; Fechtner RD; Khouri AS
    Can J Ophthalmol; 2015 Apr; 50(2):132-6. PubMed ID: 25863853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of ocular surface disease in glaucoma patients.
    Leung EW; Medeiros FA; Weinreb RN
    J Glaucoma; 2008 Aug; 17(5):350-5. PubMed ID: 18703943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Signs and symptoms of ocular surface disease in patients on topical intraocular pressure-lowering therapy].
    Gomes B; Turiel PR; Marques FP; Bernardo FP; Safady MV; Portes AL; Santhiago MR
    Arq Bras Oftalmol; 2013 Oct; 76(5):282-7. PubMed ID: 24232941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
    Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
    J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
    Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
    Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].
    Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K
    Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors to develop ocular surface disease 
in treated glaucoma or ocular hypertension patients.
    Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
    Eur J Ophthalmol; 2013; 23(3):296-302. PubMed ID: 23335308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Ocular Surface Disease in Patients With Glaucoma: Clinical Parameters, Self-report Assessment, and Keratograph Analysis.
    Portela RC; Fares NT; Machado LF; São Leão AF; de Freitas D; Paranhos A; Prata TS; Gracitelli CPB
    J Glaucoma; 2018 Sep; 27(9):794-801. PubMed ID: 29916999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
    Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
    J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma.
    Agnifili L; Brescia L; Scatena B; Oddone F; Figus M; Perna F; Doronzo E; D'Ugo E; Mastropasqua L
    J Glaucoma; 2020 May; 29(5):374-380. PubMed ID: 32079993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spanish multicenter tafluprost tolerability study.
    Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM
    Br J Ophthalmol; 2012 Jun; 96(6):826-31. PubMed ID: 22399693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.